VEGFA and retinopathy of prematurity: Out of 53 respondents, anti-VEGF was preferred among clinicians treating posterior disease (A-ROP [64.1%], Type 1 ROP in zone 1 [71.7%], posterior zone 2 [56.6%]) and laser monotherapy preferred in anterior disease (Type 1 ROP in anterior zone 2 [73.6%], Type 1 ROP in zone 3 [79.2%]).